MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

153.07 +3.29 (+2.20%)
Streaming Delayed Price Updated: 10:29 AM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Repligen (NASDAQ:RGEN) Combines Strong Growth with a Promising Technical Breakout Setup ↗
Via Chartmill
News headline image
Why Repligen (RGEN) Stock Is Up Today
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 14.6% in the afternoon session after the company reported ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Repligen Q2 Earnings Call Highlights ↗
Repligen (NASDAQ:RGEN) reported second-quarter 2026 revenue of $204 million, up 12% year over year on a reported basis and 13% organically, as demand for proteins, analytics products and recurring... 
Via MarketBeat
Topics Earnings
Which stocks are gapping on Tuesday? ↗
Via Chartmill
Repligen (NASDAQ:RGEN) Rallies as Quality Stock Delivers Earnings Beat ↗
Via Chartmill
Repligen Corp (NASDAQ:RGEN) Sees Pre-Market Gain After Q1 Earnings Beat Offsets Slight Revenue Miss ↗
Via Chartmill
Topics Earnings
News headline image
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 11.9% ... 
Via StockStory
News headline image
Repligen (RGEN) Q2 Earnings: What To Expect
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday morning. Here’s what you need to know. Repligen bea... 
Via StockStory
News headline image
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HC... 
Via StockStory
News headline image
3 Cash-Producing Stocks That Concern Us
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
News headline image
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach ↗
Repligen (NASDAQ:RGEN) said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that... 
Via MarketBeat
News headline image
Why Repligen (RGEN) Stock Is Trading Lower Today
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 7% in the morning session after investors reacted to the com... 
Via StockStory
News headline image
3 Reasons RGEN is Risky and 1 Stock to Buy Instead
Over the last six months, Repligen’s shares have sunk to $139.83, producing a disappointing 16% loss - a stark contrast to the S&P 500’s 9% gain. This might ... 
Via StockStory
Topics Stocks Supply Chain
News headline image
2 High-Flying Stocks on Our Watchlist and 1 We Find Risky
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo... 
Via StockStory
News headline image
2 Profitable Stocks on Our Watchlist and 1 Facing Challenges
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
3 Out-of-Favor Stocks We Keep Off Our Radar
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a co... 
Via StockStory
News headline image
Q1 Rundown: Repligen (NASDAQ:RGEN) Vs Other Drug Development Inputs & Services Stocks
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services ind... 
Via StockStory
News headline image
Why Repligen (RGEN) Stock Is Trading Up Today
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 2.9% in the afternoon session after RBC Capital resumed co... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
1 Growth Stock with Explosive Upside and 2 Facing Headwinds
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
News headline image
Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi... 
Via StockStory
Topics Economy
News headline image
5 Revealing Analyst Questions From Repligen’s Q1 Earnings Call
Repligen’s first quarter results were met positively by the market, reflecting solid execution across core product lines and robust demand in both analytics ... 
Via StockStory
Topics Earnings
News headline image
3 Small-Cap Stocks We Steer Clear Of
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and... 
Via StockStory
News headline image
Repligen (RGEN) Shares Skyrocket, What You Need To Know
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 7.3% in the morning session after the company reported fir... 
Via StockStory
Topics Artificial Intelligence Earnings Regulatory Compliance
News headline image
Repligen (RGEN) Q1 2026 Earnings Call Transcript ↗
Repligen (RGEN) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Repligen’s (NASDAQ:RGEN) Q1 CY2026 Sales Beat Estimates
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 14.8% ... 
Via StockStory
Topics Earnings
News headline image
Repligen (RGEN) Q1 Earnings Report Preview: What To Look For
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results this Tuesday before the bell. Here’s what investors sh... 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Repligen (RGEN) Shares Are Plunging Today
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 5.3% in the afternoon session after an SEC filing revealed t... 
Via StockStory
Topics Economy Regulatory Compliance
News headline image
Envista, Baxter, Surgery Partners, Charles River Laboratories, and Repligen Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener... 
Via StockStory
Topics Economy
News headline image
1 of Wall Street’s Favorite Stock to Own for Decades and 2 We Avoid
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
1 Cash-Producing Stock Worth Your Attention and 2 We Avoid
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story